GLP1R and type 2 diabetes mellitus: Combined with the fact that semaglutide already has approval for use in Type 2 diabetes mellitus and a good safety record, there is potential for semaglutide and other GLP-1R agonists to be repurposed as neuroprotective therapeutic agents.